Last
Update:
December 08, 2014
CONFERENCE POSTER
Comparison of the Emergence of Genotypic Resistance
over 60 Weeks of Therapy
with
Lopinavir/ritonavir (Kaletra) or Nelfinavir
plus d4T/3TC.
Kempf D, Bernstein B, King M, et al.
Poster Abstract
CONFERENCE POSTER
Factors Affecting Long-Term Virologic Suppression in
Phase II Studies of
Lopinavir/ritonavir (LPV/r) in ARV-Naive or PI-Experienced
Patients.
King M, Brun S, Marsh T, et al.
Poster Abstract
Pediatric Treatment Indications |
|
CONFERENCE POSTER
Kaletra (ABT-378/ritonavir) in HIV-Infected Children
at 72 Weeks.
Cahn P, Renz C, Saez-Lorens X, et al.
Poster
Abstract
Adolescent/Adult Treatment
Indications |
|
CONFERENCE POSTER
Lopinavir/ritonavir (Kaletra) in Antiretroviral Naïve
HIV+ Patients: Week 144
Follow-Up(M97-720).
White, Jr. AC, Brun
S, King M, et al. .
Poster Abstract
CONFERENCE POSTER
Kaletra
vs. Nelfinavir in Antiretroviral-Naive Subjects: Week 60 Comparison
in a
Phase III, Blinded, Randomized Clinical
Trial.
Ruane P, Mendonca J, Timerman A, et al.
Poster Abstract
CONFERENCE POSTER
Safety
of Kaletra Data from Phase II and Phase III Clinical Trials
(M98-863;
M97-720; M97-765; M97-957)
Bernstein
B, King M, Brun S, et al.
Poster
Abstract
|